The Claim
In older adults with ischemic systolic heart failure, daily administration of 10 mg rosuvastatin for 32.8 months does not significantly reduce all-cause mortality compared to placebo, as indicated by a hazard ratio of 0.95 (95% CI, 0.86–1.05; P=0.31).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In older adults with ischemic systolic heart failure, taking 10 mg of rosuvastatin daily for about 32.8 months does not lower the risk of death from any cause compared to taking a placebo.
See the scientific wording
In older adults with ischemic systolic heart failure, daily 10 mg rosuvastatin does not significantly reduce all-cause mortality, with a hazard ratio of 0.95 (95% CI, 0.86–1.05; P=0.31), indicating no survival benefit over 32.8 months of treatment compared to placebo.
Rosuvastatin lowers cholesterol and reduces inflammation in the blood, which improves blood flow in small heart vessels and decreases hospital visits, but it does not stop the heart muscle from failing or prevent death.
What the research says
1 studyStudy: Rosuvastatin in older patients with systolic heart failure.
The study found that taking rosuvastatin every day for nearly three years didn’t help older adults with heart failure live longer than those who didn’t take it, even though it made them feel better and go to the hospital less often.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.